Annals of Emergency Medicine
Volume 52, Issue 4 , Pages 458-472 , October 2008

Acutely Decompensated Heart Failure in a County Emergency Department: A Double-Blind Randomized Controlled Comparison of Nesiritide Versus Placebo Treatment: Answers to May 2008 Journal Club Questions

  • Tyler W. Barrett, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN
    • ,
  • David L. Schriger, MD, MPH

      Affiliations

    • University of California, Los Angeles, Los Angeles, CA

References 

  1. Publication Committee for VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  2. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  3. Miller AH, Nazeer S, Pepe P, et al. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment. Ann Emerg Med. 2008;51:571–578
  4. Hauptman PJ, Schnitzler MA, Swindle J, et al. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006;296:1877–1884
  5. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37–48
  6. Glymour MM, Greenland S. Causal diagrams. In:  Rothman KJ,  Greenland S,  Lash TL editor. Modern Epidemiology. 3rd ed.. Philadelphia, PA: LippincottM; 2008;p. 183–212
  7. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e2
  8. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379–385
  9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  10. Mills RM, LeJemtel TH, Horton DP, et al. Natrecor Study Group Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999;34:155–162
  11. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure (Nesiritide Study Group). N Engl J Med. 2000;343:246–253
  12. Topol EJ. Nesiritide—not verified. N Engl J Med. 2005;353:113–116
  13. Collins SP, Hinckley WR, Storrow AB. Critical review and recommendations for nesiritide use in the emergency department. J Emerg Med. 2005;29:317–329
  14. Marx J, Hockberger R, Walls R. Rosen's Emergency Medicine. Concepts and Clinical Practice. 5th ed.. St. Louis, MO: Mosby; 2002;1122
  15. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT Study. Am Heart J. 2002;144:1102–1108
  16. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol. 2004;94:595–601
  17. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  18. Peacock W, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the Proaction Trial. J Emerg Med. 2005;29:243–252
  19. Peacock WF. Initial results from the PROACTION Study. J Emerg Med. 2006;31:435–436
  20. Saul S. Heart drug maker will lay off 150 (New York Times. February 24, 2006). http://www.nytimes.com/2006/02/24/business/24scios.htmlAccess May 20, 2008
  21. Mehrotra L, Weldon B, Caruso D. JNJ-Q4 2007 Johnson & Johnson earnings conference call: final transcript. In: Thompson Financial. Thomson StreetEvents; 2008;p. 1–25
  22. Hennessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:311–313
  23. Pearl J. Causality. New York, NY: Cambridge University Press; 2000;
  24. Greenland S, Rothman KJ, Lash TL. Measure of effect and measures of association. In:  Rothman KJ,  Greenland S,  Lash TL editor. Modern Epidemiology. 3rd ed.. Philadelphia, PA: Lippincott; 2008;p. 56–60
  25. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet. 1990;335:149–152
  26. Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13:1715–1726
  27. Diercks DB. Can we improve treatment of heart failure in the emergency department?. Ann Emerg Med. 2008;51:583–584
  28. Packer M, Lee W, Kessler P, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804
  29. Hulley S, Cummings S, Browner W, et al. Designing Clinical Research. 3rd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2007;168–169
  30. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research; 1998:1-23.
  31. US Department of Health and Human Services, Food and Drug Administration, eds. International Conference on Harmonisation: guidance on general considerations for clinical trials. Fed Reg. 1997;66113–66119
  32. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45;doi:10.1371/journal.pmed.0050045
  33. McNamee D. Review of clinical protocols at The Lancet. Lancet. 2001;357:1819–1820
  34. http://www.consort-statement.org/index.aspx?o=1210Accessed April 20, 2008
  35. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657–662
  36. Barrett TW, Schriger DL. Practical considerations in HIV testing in the emergency department, characteristics of diagnostic tests, and the role of sensitivity analysis in observational studies: answers to March 2008 Journal Club questions. Ann Emerg Med. 2008;52:170–181
  37. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994;121:200–206

 Editor's Note: You are reading answers to the third installment of Annals of Emergency Medicine Journal Club. The questions and the article they are about (Miller et al. Ann Emerg Med. 2008;51:571-578.) were published in the May 2008 issue. Information about journal club can be found at http://www.annemergmed.com/content/journalclub. Readers should recognize that these are suggested answers. We hope they are accurate; we know that they are not comprehensive. There are many other points that could be made about these questions or about the article in general. Questions are rated “novice,” (), “intermediate,” (), and “advanced” () so that individuals planning a journal club can assign the right question to the right student. The novice rating does not imply that a novice should be able to spontaneously answer the question. “Novice” means we expect that someone with little background should be able to do a bit of reading, formulate an answer, and teach the material to others. Intermediate and advanced questions also will likely require some reading and research, and that reading will be sufficiently difficult that some background in clinical epidemiology will be helpful in understanding the reading and concepts. We are interested in receiving feedback about this feature. Please e-mail journalclub@acep.org with your comments.

PII: S0196-0644(08)00787-7

doi: 10.1016/j.annemergmed.2008.05.001

Annals of Emergency Medicine
Volume 52, Issue 4 , Pages 458-472 , October 2008

Article Tools